Molecular testing for fertility-sparing endometrial cancer treatment
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether knowing the genetic profile (molecular classification) of your endometrial cancer can help guide fertility-sparing treatment. It aims to improve outcomes for young patients who want to preserve their ability to have children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old
- You have been diagnosed with early-stage endometrial cancer that has not spread into the uterine muscle
- Your cancer has an endometrioid type and is low or medium grade (grade 1 or 2)
- You want to preserve your fertility (avoid a hysterectomy)
- Your tumor can be tested for genetic markers (molecular classification)
- You have had an MRI or transvaginal ultrasound showing no spread of cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a computer model powered by artificial intelligence can better predict outcomes for people with endometrial cancer or related conditions. It uses patient data and tissue samples to see if the model can help doctors choose the best care.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.
This study uses two simple tests (a cell sample from the uterus and a cervical DNA test) to find endometrial cancer early and to check how well fertility-sparing treatment is working.
This study uses advanced genetic testing (next-generation sequencing) to look at the molecular makeup of endometrial cancer or its rare subtype, carcinosarcoma. The goal is to better understand the cancer and possibly guide more personalized treatment.
This study tests whether combining ultrasound with tissue samples can better monitor women with early-stage endometrial cancer or precancer who choose fertility-sparing treatment instead of hysterectomy. It may help preserve your ability to have children while closely tracking the disease.
Hear when a new Uterine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.